The first HIPAA-compliant controlled substance delivery platform purpose-built for pharmacies, with cryptographic audit chains and real-time DEA compliance. Positioned to capture a significant share of the $85B+ prescription delivery market.
RxRunner is positioned at the intersection of healthcare compliance and last-mile logistics.
| Tier | Monthly | Annual ARR | Target Segment |
|---|---|---|---|
| Starter | $499/mo | $5,988/yr | Independent pharmacies (1-3 locations) |
| Professional | $1,999/mo | $23,988/yr | Pharmacy chains (4-20 locations) |
| Enterprise | $9,999+/mo | $119,988+/yr | Healthcare networks, PBMs, hospital systems |
Download all due diligence materials. Documents marked 🔒 Confidential require acceptance of our NDA.
High-level overview of RxRunner's market opportunity, business model, traction, and growth strategy.
Full slide presentation covering problem, solution, market size, competitive landscape, financials, and team.
Comprehensive 40-page business plan including market analysis, go-to-market strategy, 5-year financial model, and operational roadmap.
Independent valuation analysis using DCF, comparable transactions, and revenue multiple methodologies.
IRS-issued Employer Identification Number certificate and federal tax identification documentation.
Standard Industrial Classification and North American Industry Classification System codes for RxRunner's healthcare technology operations.
HIPAA-compliant BAA per 45 CFR §164.504(e) with subcontractor table, technical safeguards, and breach notification procedures.
5-phase, 12-month product roadmap with investment estimates ($1.2M–$1.9M) tied to technical milestones.
Current founding team structure and post-acquisition org design through Phase 3 (25–40 people) with compensation ranges.
For a scheduled due diligence call or to request additional materials, contact investors@bidayax.com.
We welcome conversations with strategic investors, healthcare operators, private equity firms, and potential acquisition partners.
Investment Inquiries
Seed, Series A, and strategic investment opportunities available.
Acquisition Interest
Open to discussions with strategic acquirers in healthcare, logistics, or pharmacy.
Partnership Opportunities
Pharmacy networks, PBMs, and healthcare systems welcome.
Due Diligence Calls
Schedule a call with our CEO and technical team within 48 hours.
Direct Contact
investors@bidayax.com